Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Boehringer Ingelheim
Boehringer Ingelheim
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
Eli Lilly and Company
Genmab
Pfizer
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Eli Lilly and Company
Bayer
AstraZeneca
Amgen
UNICANCER
AstraZeneca
Merck Sharp & Dohme LLC
Summit Therapeutics
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Daiichi Sankyo
Bristol-Myers Squibb
AstraZeneca
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Institut Bergonié
Gilead Sciences
Amgen
Pfizer
Sinocelltech Ltd.
Daiichi Sankyo
Daiichi Sankyo
Summit Therapeutics
Merck Sharp & Dohme LLC
AstraZeneca
NovoCure Ltd.
Intergroupe Francophone de Cancerologie Thoracique
Merck Sharp & Dohme LLC
InSightec
Bio-Thera Solutions